Ipsen has expanded its R&D pipeline once again, agreeing a $1.8 billion alliance with Skyhawk Therapeutics focused on the development of RNA-targeting therapies for ra
From artificial intelligence and digital therapeutics to the latest in oncological research and RNA therapeutics, from developments in the CNS field to what’s what in customer experience an
Biogen has made a further push into RNA-based drug discovery via a collaboration with Envisagenics, which applies artificial intelligence RNA sequencing data to discover new drug targets an